Bionow | News

AMBLor® prognostic melanoma biomarker receives UKCA mark

Sep 3rd 2024

AMBLor is a groundbreaking histopathological biomarker test for the personal identification of early-stage melanomas at low risk of progression, post staging diagnosis.

Myricx Bio announces £90m ($114m) Series A financing to advance its novel NMTi-...

Jul 8th 2024

Myricx Bio, a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), today announced the closing of its Ser...

Study Transformative Oncology, online and part-time at The University of Manches...

Jun 24th 2024

Delivered in collaboration with the Manchester Cancer Research Centre and designed with working professionals in mind, this pioneering, patient-focussed course will give you the tools to lea...

Life sciences company LightOx raises £1.5m to develop oral cancer preventative ...

Jun 13th 2024

A Newcastle-based life sciences company has raised £1.5m worth of investment to help develop a ground-breaking treatment that could provide a treatment for patients suffering from early sta...

Lung cancer study offers further evidence on importance of screening

Jun 5th 2024

Researchers from the University of Liverpool and Queen Mary University of London have published the first study in the UK to demonstrate the benefits of lung cancer screening across socioeco...

Scientists team up with York Hospital to study DNA mutations behind blood cancer...

May 28th 2024

Over 40,000 people of all ages, from children to adults, are diagnosed with blood cancers and related disorders every year in the UK. It is a complex disease area made up of over 100 individ...

Milestone for scheme improving cancer screening among Muslim women

Mar 7th 2024

“It has been a great privilege to be part of a project which empowers women to prioritise their health"

Oncology & Precision Medicine: exploring the relationship between two key areas ...

Nov 17th 2023

Following the success of 2022’s event, the Oncology & Precision Medicine Conference once again took place over two days to facilitate a more in-depth programme, with 149 delegates meeting...

University secures £2.66m to develop personalised cancer treatment

Sep 15th 2023

University of Liverpool researchers have secured £2.66m Medical Research Council funding to clinically test a novel immunotherapeutic strategy for non-small cell lung cancer – one of the ...

Ground-breaking Cancer Research at the University of Huddersfield leading to EPS...

Jan 30th 2023

Following publication in prestigious journal Nature Communications, Huddersfield researchers have been awarded an EPSRC grant to further their studies in the selectivity of compounds in canc...

Combined In Silico and In Vitro Evidence Supporting an Aurora A Kinase Inhibitor...

Jan 13th 2023

Martin Slater, Director at Cresset Discovery reviews our recent published collaboration with University of South Australia

Oncology & Precision Medicine: bringing together cancer prevention and cutting-e...

Oct 27th 2022

For the first time in 2022, the Oncology & Precision Medicine Conferences were a two-day event with 120 delegates coming together to discuss the current oncology landscape and the future of ...

News